Kroger Specialty Pharmacy Recalls Bethkis Ampules Due to Processing Control Issues
Kroger Specialty Pharmacy is recalling Bethkis 300 mg/4 mL ampules due to a lack of processing controls. The affected product was distributed in five states.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the source text does not report any illnesses, injuries, or specific high-risk pathogens, fitting the criteria for a moderate severity voluntary precautionary recall.
Plain-English summary
Kroger Specialty Pharmacy, Inc. is recalling Bethkis 300 mg/4 mL Ampule #56 (NDC 10122-0820-56), a 56-day supply. The recall was initiated because of a lack of processing controls.
The affected product was distributed in Mississippi, Louisiana, Arkansas, Illinois, and Florida. The recall includes all lots remaining within expiry that were dispensed between December 1, 2017, and February 12, 2018.
Consumers who have this product should contact their healthcare provider or the pharmacy for further instructions on how to proceed.
The recalled product
- Product
- Bethkis 300 mg/4 mL Ampule #56 NDC 10122-0820-56 56 days supply
- Manufacturer
- Kroger Specialty Pharmacy, Inc.
- Category
- Drug — Injectable Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots remaining within expiry dispensed 12/01/2017 through 02/12/2018
Distribution
Part of a larger recall action
This product is one of 67 recalled by Kroger Specialty Pharmacy, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 67 products in this recall →Related recalls
Same manufacturer · Kroger Specialty Pharmacy, Inc.
See all →- HighKroger Recalls Botox Due to Lack of Processing Controls
FDA (Drugs) · 2018-05-16
- HighKroger Recalls Capecitabine Tablets Due to Lack of Processing Controls
FDA (Drugs) · 2018-05-16
- ModerateKroger Specialty Pharmacy Recalls Cimzia 200 mg/mL PFS Kits
FDA (Drugs) · 2018-05-16
- HighKroger Recalls Lupron Depot Due to Lack of Processing Controls
FDA (Drugs) · 2018-05-16
- ModerateKroger Specialty Pharmacy Recalls Cyclophosphamide Capsules Due to Processing Controls
FDA (Drugs) · 2018-05-16
Same hazard · processing control deficiency
See all →- ModerateDoxycycline oral suspension recalled for insanitary manufacturing conditions
FDA (Drugs) · 2022-07-13
- ModerateMasterPharm Recalls Testosterone/Anastrozole Pellets Due to Processing Control Deficiencies
FDA (Drugs) · 2020-08-05
- SevereRedline Pharmacy Recalls Morphine Sulfate Due to Processing Control Deficiencies
FDA (Drugs) · 2020-03-18
- SevereRedline Pharmacy Recalls Ertapenem Injectable Due to Processing Control Issues
FDA (Drugs) · 2020-03-18
- SevereRedline Pharmacy Recalls Vancomycin Injectable Due to Processing Control Deficiencies
FDA (Drugs) · 2020-03-18
Similar recalls
- ModerateRedline Pharmacy Recalls Daptomycin Injectable Due to Processing Control Issues
FDA (Drugs) · 2020-03-18
- SevereRedline Pharmacy Recalls Vancomycin Injectable Due to Processing Control Deficiencies
FDA (Drugs) · 2020-03-18
- SevereRedline Pharmacy Recalls Ertapenem Injectable Due to Processing Control Issues
FDA (Drugs) · 2020-03-18
- ModerateMasterPharm Recalls D-Biotin 300 mg Capsules Due to Processing Control Deficiencies
FDA (Drugs) · 2020-08-05
- HighFDA Recalls Bevacizumab Due to Lack of Assurance of Sterility
FDA (Drugs) · 2014-01-22
- SevereRedline Pharmacy Recalls Morphine Sulfate Due to Processing Controls
FDA (Drugs) · 2020-03-18